Autolus Therapeutics Ltd reported $130.92M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
AstraZeneca USD 7.56B 1.85B Mar/2026
Autolus Therapeutics Ltd USD 130.92M 26.79M Mar/2026
Hikma Pharmaceutical USD 236M 48M Jun/2025
Novartis USD 6.88B 4.56B Mar/2026
Roche Holding CHF 7.55B 579M Jun/2025
Silence Therapeutics USD 57.19M 4.77M Jun/2025